| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 03/16/2023 | 125.99% | JP Morgan | $12 → $8 | Maintains | Neutral |
| 01/27/2023 | 69.49% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 01/24/2023 | 12.99% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 97.74% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 125.99% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 154.24% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 182.49% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 97.74% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 210.73% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 464.97% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 351.98% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1453.67% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1594.92% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 945.2% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 888.7% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 2216.38% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1764.41% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1171.19% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 1284.18% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
What is the target price for Atea Pharmaceuticals (AVIR)?
The latest price target for Atea Pharmaceuticals (NASDAQ: AVIR) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $0.00 expecting AVIR to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
The latest analyst rating for Atea Pharmaceuticals (NASDAQ: AVIR) was provided by JP Morgan, and Atea Pharmaceuticals downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.54, which is out of the analyst's predicted range.
